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Hormonal therapyAbstract Background: The current debate on overdiagnosis and overtreatment of
screen-detected ductal carcinoma in situ (DCIS) urges the need for prospective studies to
address this issue. A substantial number of DCIS lesions will never form a health hazard, par-
ticularly if it concerns non- to slow-growing low-grade DCIS. The LORD study aims to eval-
uate the safety of active surveillance in women with low-risk DCIS.
Design: This is a randomised, international multicentre, open-label, phase III non-inferiority
trial, led by the Dutch Breast Cancer Research Group (BOOG 2014-04) and the European
Organization for Research and Treatment of Cancer (EORTC-BCG 1401). Standard66 CX
Slaets),
appel@
1498 L.E. Elshof et al. / European Journal of Cancer 51 (2015) 1497–1510Active surveillance treatment will be compared to active surveillance in 1240 women agedP45 years with asymp-
tomatic, screen-detected, pure low-grade DCIS based on vacuum-assisted biopsies of micro-
calciﬁcations only. Both study arms will be monitored with annual digital mammography
for a period of 10 years. The primary end-point is 10-year ipsilateral invasive breast cancer
free percentage. Secondary end-points include patient reported outcomes, diagnostic biopsy
rate during follow-up, ipsilateral mastectomy rate and translational research.
Feasibility: To explore interest in and feasibility of the LORD study we conducted a survey
among EORTC and BOOG centres. A vast majority of EORTC and BOOG responding cen-
tres expressed interest in participation in the LORD study. The proposed study design is
endorsed by nearly all centres.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
The introduction of population-based mammo-
graphic breast cancer screening programmes and the
implementation of digital mammography have led to
impressive increase in incidence of ductal carcinoma
in situ (DCIS) [1–7]. This increase is not clearly associ-
ated with a substantial decrease in incidence of advanced
invasive breast cancer (iBC), and since a proportion of
DCIS will either not progress to iBC or progress at a
much later stage in life, it is suggested that overdiagnosis
and resultant overtreatment exist [8–13]. Currently, in
the United States, approximately one woman is diag-
nosed with DCIS for every four women diagnosed with
iBC [7]. In the Netherlands in 2012, 14,296 women were
diagnosed with iBC and 2245 women were diagnosed
with non-invasive pre-stage breast cancer. Of these,
approximately 80% were DCIS. The European standard-
ised rate of non-invasive, pre-stage breast cancer has
increased almost ﬁvefold from 1989 to 2012 in the
Netherlands – 4.9 per 100,000 to 22.3 per 100,000.
About one in six of all DCIS cases was a low-grade dis-
order [14].
The goal in treating patients with DCIS is to prevent
development of iBC. The conventional treatment of
DCIS is similar to that of early-stage iBC, i.e. wide local
excision (WLE) often followed by radiotherapy (RT), or
mastectomy, and possibly hormonal therapy (HT). The
outcomes in patients with DCIS treated by these con-
ventional therapies are excellent, but the best way to
manage DCIS is still subject to debate.
The natural history of DCIS is not clear, since tradi-
tionally, patients diagnosed with DCIS are treated.
Therefore, series of patients not treated for DCIS are
not available [15]. However, there exists strong circum-
stantial evidence that DCIS is a non-obligate precursor
lesion of iBC [16]. Studies where DCIS was initially mis-
diagnosed as benign and treated by biopsy alone suggest
that between 50% and 85% of all DCIS will never pro-
gress into iBC [15]. From autopsy series we have learned
that the proportion of middle-aged women who har-
boured undetected DCIS ranged from 10% to 39% [17].A range of proliferative breast lesions like DCIS have
been considered risk indicators or precursor lesions and
carry a relative risk of iBC ranging from 1.2 to 10 [16].
Lobular carcinoma in situ (LCIS) is generally consid-
ered a risk indicator, inferring an increased rate of devel-
opment of iBC, either in the ipsilateral or contralateral
breast, of about 1–2% per year, and a relative risk sim-
ilar to that of DCIS (8–10) [18–23]. Strikingly, low-grade
DCIS is intensively treated, and coincidentally-found
classical LCIS is managed by active surveillance [18].
Unfortunately, accurate prognostic factors to distin-
guish potentially life-threatening DCIS from
non-hazardous pre-invasive lesions are lacking. The
aggressive subtypes require intensive treatment, but
apparently indolent DCIS might be managed by active
surveillance [24]. Progression from DCIS to iBC consti-
tutes a complex biological phenomenon [16,25]. It has
been hypothesised that breast cancer evolution can be
classiﬁed into two groups: a low- and high-grade breast
neoplasia family [16,26–30]. The low- and high-grade
multistep model of breast cancer progression based on
morphological, immunophenotypical and molecular fea-
tures described by Lopez-Garcia et al. suggests that if
low-grade DCIS progresses to invasive disease this will
be low-grade iBC with favourable characteristics in
most cases and survival rates after treatment of this
invasive cancer will still be excellent. This model is sup-
ported by other studies [25,31]. Furthermore, it has been
hypothesised that progression from low-grade pre-stage
breast cancer to high-grade iBC is an uncommon biolog-
ical phenomenon [16,31,32].
Four randomised controlled trials that begun
between 1985 and 1990 showed that adjuvant RT after
WLE reduced local failure rates, but did not reduce
the risk of metastases or breast cancer death for patients
with DCIS as a whole. A subgroup of patients in whom
RT can be omitted could not be identiﬁed [33–36]. Few
studies prospectively evaluated the outcomes after WLE
only in a subgroup of DCIS patients. The Eastern
Cooperative Oncology Group (ECOG) 5194 trial (low-
or intermediate-grade DCIS 62.5 cm or high-grade
DCIS 61.0 cm excised with ﬁnal margins P3 mm)
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invasive ipsilateral breast events occurred in 565 women
with low/intermediate-grade DCIS treated by WLE only
[37]. Wong et al. performed a phase II, single-arm,
prospective trial in patients with small low- or interme-
diate grade DCIS, and wide excision with ﬁnal micro-
scopic margins P1 cm. Among 143 patients treated by
WLE only, only six developed an invasive local recur-
rence as ﬁrst event within 8 years [38].
Strong imaging markers to guide therapy decisions in
DCIS have been lacking. Studies have shown that mag-
netic resonance imaging (MRI) is more sensitive than
mammography for identifying iBC, and – in particular
high and intermediate grade – DCIS [39–44]. The poten-
tial role of MRI in the routine diagnostic workup of
DCIS is controversial [45,46]. It might be a useful tool
to diminish the overtreatment of indolent
screen-detected lesions, and prevent the undertreatment
of aggressive DCIS and underestimated invasive disease.1.1. Rationale
The question has been raised whether intensive treat-
ment for low-risk DCIS might be considered overtreat-
ment [47]. A substantial number of DCIS lesions will
never form a health hazard, particularly if it concerns
non- to slow-growing low-grade DCIS. This implies that
many women might be unnecessarily going through
intensive treatment resulting in a decrease in quality of
life and an increase in health care costs, without any sur-
vival beneﬁt. The LORD (LOw Risk Dcis) study is a
randomised, international, multicentre, open-label,
phase III non-inferiority trial that assesses the safety
of active surveillance in women with low-risk DCIS.
The leading groups are the Dutch Breast Cancer
Research Group (BOOG) and the European
Organisation for Research and Treatment of Cancer
(EORTC). To explore interest in and feasibility of the
LORD study, to map standard approach of low-risk
DCIS in diﬀerent countries and to investigate the possi-
ble role of MRI in the LORD study, we conducted a
survey among EORTC and BOOG centres. Here we
present the LORD study protocol and discuss the results
of the explorative feasibility survey.2. Design
2.1. Objectives of the trial
2.1.1. Primary objective
The primary objective of the LORD study is to deter-
mine whether low-grade DCIS can safely be managed by
an active surveillance strategy or that conventional treat-
ment, being either WLE alone, WLE + RT, or mastec-
tomy, and possibly HT, followed by active surveillance,
will remain standard of care. Safety will be measuredby ipsilateral invasive breast cancer-free percentage at
10 years (10-year iiBC-free%). Details on the primary
end-point will be discussed in the statistical section.2.1.2. Secondary objectives
Secondary objectives/end-points of the LORD
include:
- Patient reported outcomes
- Cost-eﬀectiveness
- Central collection of imaging data and bio samples
for future translational research purposes
By integrating clinical, imaging, morphological and
molecular data of both retrospective DCIS series and
the prospective LORD study, we aim at developing a
tool, reliably distinguishing harmless from aggressive
screen-detected DCIS, that may help clinicians and
women with DCIS to decide between management by
active surveillance or more intensive treatment.
- Rate of invasive disease at ﬁnal pathology specimen
in the conventional treatment arm
- Rate of DCIS grade II/III at ﬁnal pathology speci-
men in the conventional treatment arm
- Biopsy rate during follow-up
- Ipsilateral mastectomy rate
- Time to ipsilateral DCIS grade II/III
- Time to contralateral DCIS grade I/II/III
- Cumulative incidence of contralateral invasive breast
cancer
- Time to failure of active surveillance strategy in the
experimental arm, i.e. time to crossover to conven-
tional treatment, due to any cause
- Distant metastases free interval
- Overall survival2.2. Patient selection criteria
2.2.1. Inclusion criteria
Women aged 45 years or older with asymptomatic,
pure and low-grade DCIS based on vacuum-assisted
biopsies (VACB) of microcalciﬁcations only, detected
by population-based or opportunistic screening mam-
mography, are eligible if they have an American
Society of Anaesthesiologists (ASA) score of 1–2 and
life expectancy of more than 5 years. Prior surgery of
the ipsilateral breast because of benign lesions is
allowed. Before randomisation, written informed con-
sent must be given according to ICH/GCP and natio-
nal/local regulations.2.2.2. Exclusion criteria
Individuals will be excluded from the trial if they have
personal history of DCIS or iBC, or if a BRCA1 or
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ily. Other exclusion criteria are symptomatic DCIS, i.e.
DCIS detected by palpation or nipple discharge, bilat-
eral DCIS, synchronous contralateral iBC, LCIS,
Paget’s disease, or invasive breast disease on cytology
or histology and serious disease that precludes deﬁnitive
surgical treatment.Fig. 1. Flow chart of diagnostic workup prior to randomisation.2.3. Participant recruitment
Patients will be recruited at participating trial sites
across diﬀerent countries, i.e. breast centres, highly spe-
cialised gynaecologic departments or gynaecological
and oncological outpatient units. Patients whose diag-
nostic core biopsy – as standard of care – of
screen-detected microcalciﬁcations shows histologically
conﬁrmed unilateral primary low-grade DCIS of the
breast by local pathology will be able to participate
in the LORD study. Only if the informed consent form
is obtained, and inclusion and exclusion criteria are
compliant, the patient can be enrolled into the study.
Patients who are not registered prior to any
trial-related procedure cannot be accepted for the trial
at a later time.2.4. Diagnostic workup before randomisation (Fig. 1)
Population-based or opportunistic screening mam-
mography should reveal lesions consisting of microcal-
ciﬁcations only. A minimum of six cores with VACB of
the microcalciﬁcations must be taken, and a marker
should be placed at the biopsy site. The biopsy speci-
men will be considered representative if a substantial
amount of microcalciﬁcations is found in two or more
of the biopsies or if more than 75% of the microcalci-
ﬁcations is removed in one of the cores, and this
should be proven by specimen radiography. The deﬁni-
tion of grade I DCIS described by Schnitt and Collins
will be adhered to [48]. Key features of low-grade
DCIS include:
Cytologic features:
- Monotonous, uniform, rounded cell population
- Subtle increase in nuclear-cytoplasmic ratio
- Equidistant or highly organised nuclear distribution
- Rounded nuclei with inconspicuous nucleoli
- Hyperchromasia may or may not be present
Architectural features:
- Cribiform, micropapillary or solid patterns most
frequent
- Bridges and arcades, when present, of uniform
thickness
- Cells polarise around extracellular lumens
- Comedo necrosis rareIn case of extended (>4 cm) DCIS grade I, VACB
from the centre of the lesion and a peripheral part, or
two peripheral parts of the lesion must be taken. In case
of multicentricity two locations of clusters in diﬀerent
quadrants must be biopsied. Radiological and patholog-
ical ﬁndings should correlate, i.e. both ﬁndings should
conﬁrm low-grade DCIS and no suspicion of
intermediate-grade or high-grade DCIS or iBC should
exist.2.5. Study design
The LORD trial will be an international multicentre,
phase III, open-label, randomised non-inferiority study.
Individuals will be randomised in equal numbers to one
of the following arms: active surveillance or standard
treatment according to local policy, followed by active
surveillance. Study centre will be included in the stratiﬁ-
cation of this trial. Randomisation will take place within
12 weeks after histologically proven low-grade DCIS on
VACB. A computer-based allocation using theminimisa-
tion method with a random component will be used for
the randomisation procedure. Surgery in the
standard arm will take place within 8 weeks after
randomisation.2.6. Study arms
The trial will compare standard treatment according
to local policy and an active surveillance strategy in
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Fig. 2):
2.6.1. Experimental arm
Active surveillance, i.e. monitoring by annual digital
mammography for a period of 10 years, and treatment
if there is any sign of progression to higher-grade
DCIS or invasive cancer.
2.6.2. Standard arm
Standard treatment according to local policy. This
can be either WLE alone, WLE + RT, or mastectomy,
and HT by Tamoxifen will be allowed. In case invasive
disease is found at ﬁnal pathology after surgery, patients
should be treated and followed up according to local
policy. The same follow-up scheme will be applied in
both study arms, i.e. annual mammography for a period
of 10 years.
2.7. Clinical evaluation and follow-up
Timing of follow-up visits will be based on the date of
registration. Follow-up mammograms will be scheduled
annually from the date of registration for 10 years in
both study groups. Fig. 3 shows a decision tree to be
used for additional diagnostics during follow-up.
Biopsy during follow-up will be recommended in case
of an increase of >30% of the largest diameter of the
index lesion on mammography as compared to the
mammography performed one year after the initial
VACB. The lesion to act upon must be at least 1 cmLow-Risk DCIS
Annual Mammography 
for a period of 10 years
Surgery (WLE or MX)
+/- Radiotherapy
+/- Hormonal therapy
Active Surveillance
Annual Mammography 
for a period of 10 years
R
Standard Arm
n = 620
Experimental Arm
n = 620
Fig. 2. Flow chart of study design. R = randomisation. WLE = wide
local excision. MX = mastectomy.in diameter. Biopsy will also be strongly recommended
in case of suspicion of malignancy according to the
BIRADS criteria of the American College of
Radiology [49].2.8. Statistical considerations
2.8.1. Primary end-point
Safety will be measured by ipsilateral invasive breast
cancer–free percentage at 10 years (10-year iiBC-free%).
Regional and distant metastases and death from breast
cancer in the absence of iiBC will also count as events
in this deﬁnition. This deﬁnition is in line with the deﬁ-
nition of recurrence free-interval in the adjuvant setting
[50]. If the primary DCIS is excised and ﬁnal pathology
concludes invasive disease, this incidence will not count
as an event for the primary end-point. These patients
will not be excluded from the study and/or analysis
and will be followed for events from surgery onwards.2.8.2. Hypotheses
We have applied the following null and alternative
hypotheses (H0 and H1 respectively):
H0 (inferiority of active surveillance):
10-year iiBC-free% active surveillance arm 6 10-year
iiBC-free% standard arm  10%.
H1 (‘non-inferiority’ of active surveillance):
10-year iiBC-free% active surveillance armP 10-year
iiBC-free% standard arm  5%.
We have re-formulated the design assumptions based
on 5-year iiBC-free%, presuming a fairly constant event
rate over time [33–38,51–58]. We have assumed that the
mastectomy rate in the standard treatment arm is 20%
and that the 5-year iiBC-free% equals 100% for this
treatment. Furthermore, we have assumed that the
breast-conserving treatment rate in the standard treat-
ment arm is 80% and that the 5-year iiBC-free% equals
97% for this treatment. Given these percentages it is pre-
sumed that the 5-year iiBC-free% in the standard treat-
ment arm equals 97.5%, and the 10-year iiBC-free%
equals 95%.2.8.3. Primary test
The 10 year iiBC-free% will be estimated based on the
Weibull survival model for the time to iiBC in each
treatment arm separately. The diﬀerence between these
two estimates will be compared with a critical value of
6.45. The primary test will be conducted in the per pro-
tocol population, consisting of all eligible patients who
eﬀectively started in the randomised treatment arm.2.8.4. Sample size
With a one-sided test for non-inferiority with
alpha = 0.025 and a power of 80%, 930 patients need
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to fulﬁl a follow-up period of at least 10 years. We antic-
ipate that 25% of all randomised patients will be
excluded from the per protocol population, or will have
dropped out before the end of the 10-year follow-up per-
iod, and therefore 1240 low-grade DCIS patients need to
be randomised. Accrual is expected to take 4 years,
resulting in an estimated total study duration of
14 years.
The power for this trial design ﬂuctuates slightly for
diﬀerent plausible 10-year iiBC-free percentages in the
standard treatment arm as shown in Table 1. Table 1
also takes into account a non-binding interim analysis
for futility (see below) and a parametric Weibull estima-
tion of the 10-year iiBC-free%.
2.8.5. Interim analysis
One non-binding interim look for futility is planned
when 742 patients have fulﬁlled a follow-up period of
5 years. This is estimated to occur 7.6 years after accrual
of the ﬁrst patient. The 5-year iiBC-free% will be esti-
mated based on the Weibull survival model for the time
to iiBC in each treatment arm separately. The diﬀerence
between these two estimates will be compared with a
critical value of 4.91.Table 1
Simulated design characteristics (30,000 simulation runs for ea
for the 10-year ipsilateral invasive breast cancer-free percentag
The table contains the simulated power and signiﬁcance leve
account a Weibull estimate of the 10-year ipsilateral invasive b
for futility.
10-year iiBC-free% = 10-year ipsilateral invasive breast cancerSimulated operating characteristics of the interim
look are illustrated in Table 2.
2.8.6. Statistical analysis
The primary analysis will be based on the per proto-
col population (see primary test section), and will be
supplemented with an intention-to-treat analysis. A
multivariate analysis will be performed using a cox pro-
portional hazards regression model.
3. Feasibility
In May 2014 a survey was released to the EORTC
and BOOG networks. This survey aimed to explore
interest in and feasibility of the LORD trial, to map
standard approach of low-risk DCIS in diﬀerent coun-
tries, and to investigate the possible role of MRI in this
trial.
3.1. Methods
A team of clinical breast cancer experts, which con-
sisted of a surgeon, pathologist, radiologist, radiothera-
pist, medical oncologist, nurse practitioner, and
statistician, developed the survey items.ch setting). As per planned design in grey. Five scenarios
e in the standard arm are considered.
l under the planned design for each scenario, taking into
reast cancer-free percentage and a non-binding interim test
-free percentage.
Table 2
Simulated operating characteristics of the interim look (30,000 simulation runs for each setting). As per planned design
marked in grey.
Five diﬀerent scenarios are considered for the 5-year ipsilateral invasive breast cancer-free percentage in the standard arm
(ﬁrst column). The ﬁve scenarios in this column correspond to those in Table 1 given a constant event rate over
time.Columns 2–4 contain the operating characteristics of the interim look under three diﬀerent scenario’s regarding the
diﬀerence in 5-year ipsilateral invasive breast cancer-free percentage between the standard and experimental arm.5-yr
iiBC-free% = 5-year ipsilateral invasive breast cancer-free percentage.
10-yr iiBC-free% = 10-year ipsilateral invasive breast cancer-free percentage.
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A total of 53 centres from 14 diﬀerent countries
responded to the survey. Most responding centres were
from the Netherlands (36%), Belgium (25%), and
France (11%). Other responding centres were from
Egypt, Greece, Israel, Italy, Poland, Portugal, Serbia,
Slovenia, Spain, Sweden and Turkey.
3.2.1. Interest and feasibility
More than three quarters of the responders were inter-
ested in participation in the study (77%). Twelve centres
that reported not to be interested were from Belgium
(6/13 responding centres), France (3/6), Greece (1/2),
Israel (1/1) and Sweden (1/1). Reasons for no interest
could be subdivided into three main issues: accrual diﬃ-
culties (n = 5), not convinced by study design or ratio-
nale (5) and administrative issues (1) (1 missing).
Further presentation of the survey results is based
on the answers of centres that expressed interest
(n = 41) and shown in Table 3.The reported numbers resulted in an estimated total
of around 400 low-grade screen-detected DCIS patients
per year in the interested centres. 90% of the centres
believed that low-grade DCIS patients would be willing
to participate in the LORD study. Three centres, from
Greece, the Netherlands and Turkey, that thought that
patients would not be willing to participate, expected
that most patients would demand surgery.
3.2.2. Current management of DCIS
3.2.2.1. Screening. Most screening programmes apply a
lower age limit of 50 years. In Italy and Portugal a lower
age limit of 45 years was reported (four centres), and
one centre in Turkey reported a limit of 40 years.
3.2.2.2. Treatment. To assess the current treatment of
DCIS, centres were allowed to give multiple answers.
The most frequently oﬀered treatment approach of
DCIS was WLE followed by RT: 95% of the centres
reported to oﬀer this approach as one of the treatment
options, which means that 5% of the centres reported
1504 L.E. Elshof et al. / European Journal of Cancer 51 (2015) 1497–1510not to oﬀer WLE + RT to DCIS patients. A minority of
the centres reported to oﬀer HT (all Tamoxifen) (29%).
Of the centres that reported to oﬀer HT as one of the
treatment options, ﬁve were from Belgium, two from
Italy, and one from Poland, Portugal, Serbia, Spain
and Turkey each.
3.2.2.3. Diagnostic workup and follow-up. The proposed
diagnostic workup and follow-up strategy in the
LORD study was endorsed by most centres (85% and
90%, respectively). Centres that reported to employ dif-
ferent diagnostic workup of DCIS (n = 5) explained that
they would take less biopsies in the diagnostic process.
Centres that reported not to feel comfortable to comply
with the follow-up scheme (n = 4), would like to add a
mammography 6 months after the ﬁrst diagnosis, or
every 6 months, and would recommend attenuating the
deﬁnition of progression.
3.2.3. MRI
The majority of the interested centres preferred not to
add an MRI to the diagnostic workup in the trial (66%).
4. Discussion leading to rationale and design of the
LORD trial
4.1. Considerations and arguments
The current debate on overdiagnosis and overtreat-
ment of screen-detected breast cancer and pre-invasive
breast lesions urges the need for prospective studies to
address these issues. With the increased use of screening
mammography, the likelihood of detecting DCIS is con-
siderable with 20% of all screen-detected breast cancer
cases. No randomised trial has compared WLE + RT
with mastectomy for the treatment of DCIS, but four
randomised controlled trials have addressed the value
of adding RT to WLE [59–62]. Controversy exists pri-
marily because of the absence of randomised trials doc-
umenting that treatment improves survival and quality
of life. Because almost all DCIS is excised when
detected, uncertainty about the natural history exists,
and the clinical signiﬁcance of screen-detected DCIS is
debated. It is suﬃciently clear that DCIS represents a
heterogeneous group of diseases, and it is time to
address the safety of active surveillance in women with
screen-detected low-risk DCIS in order to reduce the
negative impact of identifying and treating non-lethal
disease.
The LORD study aims to contribute to solve a sub-
stantial clinical dilemma in breast cancer diagnosis and
treatment: ﬁnding the balance between overdiagnosis
and undertreatment in individuals with low-risk DCIS
of the breast. We believe it is reasonable to assume that
active surveillance is nearly as safe as the conventionalmanagement of screen-detected low-grade DCIS in
terms of the 10-year ipsilateral invasive breast cancer
free rate and consequently the related survival. For
our sample size calculation we have assumed a slightly
decreased 5-year iiBC-free rate in the experimental
arm, as opposed to the standard treatment arm. Data
on the natural history of DCIS are not well established,
and therefore we also based our assumptions on data on
similar low-risk non-obligate precursor lesions, like
LCIS and atypical hyperplasia. We hold the position
that our assumed iiBC-free rate in the active surveillance
arm, in relation to the expected iiBC-free rate in the
standard treatment arm, is clinically acceptable with
broad clinical support [63].
4.2. Ipsilateral invasive breast cancer-free rate
When discussing the trade-oﬀ of an acceptable
iiBC-free rate, the potential beneﬁts of not treating
should also be taken into account. Active surveillance
does not remove DCIS, and may therefore miss an
opportunity to end or delay disease progression.
However, despite a slightly higher chance of developing
iiBC, we concur that active surveillance may save a sub-
stantial number of women from going through surgery
and radiotherapy, avoiding possible harmful
side-eﬀects of treatment, and as a consequence, this
may lead to an improved quality of life (cosmetic out-
comes, body self-image, self-esteem, etc.). Of course,
the potential distress caused by ‘no treatment’ will be
actively evaluated in the LORD study in order to gain
a well-balanced insight into patient reported outcomes.
Furthermore, the evaluation of health economics data
might show that an active surveillance strategy will lead
to a decrease in health care costs. Cost-eﬀectiveness
research will allow patients, health care providers and
payers to better understand the true value of each
disease-management strategy.
One other important argument to assume that the
expected iiBC-free rates in this low-risk DCIS popula-
tion are clinically acceptable is provided by the circum-
stantial evidence that there is a diﬀerence in natural
history between high-grade and low-grade DCIS. If
low-grade DCIS progresses to iBC, this is most likely
to be low-grade iBC [16,25,31]. After an active surveil-
lance strategy of a low-grade DCIS lesion, multiple
treatment options of the subsequent low-grade iBC will
still be feasible and excellent long-term survival out-
comes can be preserved. Subsequent high-grade iBC is
unlikely to develop from low-grade DCIS, and will more
likely be a new primary tumour [16,31,32]. Women man-
aged by an active surveillance strategy, as well as women
treated by WLE for DCIS will have a chance of develop-
ing new primary breast cancer, but the breast-conserving
options might be more limited in the latter group.
Table 3
Survey results based on the answers of centres that expressed interest (n = 41).
n %
Interest and feasibility
How many patients with screen-detected ductal carcinoma in situ (DCIS) do you see in your hospital per year?
625 16 39
26–50 13 32
>50 12 29
What percentage of the screen-detected DCIS lesions are low-grade (grade 1)?
65% 5 12
6–15% 13 32
16–25% 10 24
>25% 9 22
Missing 4 10
Do you think that these low-grade DCIS patients will be willing to participate in this trial?
Yes 37 90
No 3 7
Missing 1 2
Current management of DCIS
Is there a population-based screening programme in your country?
Yes 36 88
No 4 10
Missing 1 2
If yes, How is the screening programme organised? (n = 36)
Frequency Biannual 35 97
Missing 1 3
Location Screening unit 29 81
Hospital 4 11
Other 2 6
Missing 1 3
Participation rate estimate <50% 5 14
50–79% 14 39
P80% 10 28
Missing 7 19
Lower age limit 40 years 1 3
45 years 4 11
50 years 30 83
Missing 1 3
Upper age limit 65 years 3 8
69–70 years 11 31
74–75 years 21 58
How are patients with DCIS treated in your hospital? (several options are possible)
No treatment 0 0
Excision biopsy 8 20
Wide local excision 16 39
Wide local excision + radiotherapy 39 95
Mastectomy 23 56
Hormonal therapy 12 29
Does the work-up scheme which is described in the outline reﬂect the standard of practice in your hospital?
Yes 35 85
No 5 5
Missing 1 1
Is the work-up of DCIS in your hospital considered standard in your entire country?
Yes 38 93
No 3 7
Are you comfortable to comply to the follow-up ﬂow-chart described in the outline?
Yes 37 90
No 4 10
Magnetic resonance imaging (MRI)
Are you using MRI in the work-up of low-grade DCIS?
Yes, routinely 2 5
Yes, in special cases 21 51
No, never 18 44
Is MRI in the work-up of DCIS reimbursed in your country?
Yes 28 68
No 11 27
(continued on next page)
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Table 3 (continued)
n %
Missing 2 5
Would you prefer to add an MRI to the work-up in this trial?
Yes 14 34
No 27 66
If an additional MRI in the work-up of DCIS leads to a diagnosis of histologically proven high grade DCIS or invasive breast cancer (upgrading)
would you then include MRI in your standard work-up?
Yes, if MRI leads to an upgrade in at least 5% of patients 10 24
Yes, if MRI leads to an upgrade in at least 10% of patients 14 34
Missing 17 42
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The LORD study includes all current DCIS treat-
ment strategies within the standard treatment arm. A
multi-arm design was not considered feasible because
this would lead to a non-feasible increase in sample size.
Furthermore, we concluded from our discussions that
the study should reﬂect the current standard clinical
practice as much as possible. We will stratify by centre
to strive for an equal contribution of all preferred cur-
rent practice approaches in both study arms, and more-
over, the stratiﬁcation accounts for small diﬀerences in
the diagnostic workup and follow-up of the study indi-
viduals. The option to exclude mastectomy from the
standard treatment arm, because of its deviant
iiBC-free rate, was abandoned. Either way, some
women will end up undergoing a mastectomy in this
treatment arm as a result of positive margins.
The use of HT in the treatment of DCIS diﬀers
among and within the anticipated participating coun-
tries. In the Netherlands for example, HT is generally
not oﬀered to patients with pure DCIS. Because of the
international multi-centre design of the LORD the use
of HT is allowed in the standard arm. However, its
use is not allowed in patients within the active surveil-
lance arm.4.4. Age
The lower age limit for inclusion in this trial was set
at 45 years. In most screening programmes women from
the age of 50 years are targeted. However, in our survey,
four centres reported a lower age limit of 45 years to be
applicable in their screening programme. Women with a
history of any grade DCIS younger than 40 or 50 years
have an increased risk of developing iBC than older
women [7]. We discussed not to exclude potential trial
participants between 45 and 50 years, because the
division between ‘young’ and ‘old’ is arbitrary and
variable between studies, and it is believed that
women with screen-detected, asymptomatic low-grade
DCIS have a favourable long-term outcome as
opposed to women with symptomatic disease.4.5. Central review
The LORD trial does not apply pre-randomisation
central pathology or imaging review. Literature shows
that classifying low-risk in situ lesions is associated with
signiﬁcant interobserver variation [64–68]. This suggests
that some true low-grade DCIS lesions are missed,
whereas other lesions are classiﬁed as DCIS incorrectly.
This could be an indication to use pre-randomisation
central pathology review by expert pathologists.
However, in daily practice treatment decisions are based
on the pathology reports assessed by local pathologists.
Both downgraded and upgraded lesions will appear to
some extent in the study population as well as in the real
population. Furthermore, central pathology review
involves complicated and expensive logistics owing to
enrolment of large numbers of patients in multiple coun-
tries and requires long turnaround time for slide review
at the central location.
In the LORD study we pursue the deﬁnition of
low-grade DCIS as described in the book Biopsy
Interpretation of the Breast written by Schnitt and
Collins [48]. Tissue blocks of pre-randomisation
VACB and resection specimens, as well as digital mam-
mography data will be collected for retrospective central
review and future translational research purposes.4.6. MRI
Mammography is the mainstay for diagnosing DCIS.
However, MRI of the breast has the ability to enhance
additional ﬁndings in women when performed after ini-
tial clinical evaluation. Yet, the clinical relevance of
these additional ﬁndings is uncertain [46,69,70].
During protocol development, the possibility of adding
pre-randomisation MRI to the diagnostic workup has
been discussed. The advantages of pre-randomisation
MRI include improved sensitivity and therefore
increased ability to detect intermediate-grade or
high-grade DCIS, and iBC, which are considered exclu-
sion criteria in the LORD trial. In spite of improved sen-
sitivity a retrospective cohort study showed no
association between the perioperative use of MRI and
L.E. Elshof et al. / European Journal of Cancer 51 (2015) 1497–1510 1507local–regional recurrence rate in women undergoing
breast-conserving surgery for DCIS [71].
Currently, breast MRI is not routinely performed in
patients with DCIS, which was also reﬂected in the
results of our explorative survey. An MRI side-study
could give more insights into the role of MRI in the
diagnostic workup of screen-detected DCIS. However,
the majority of centres that showed interest in participa-
tion in the LORD trial were not in favour of adding
MRI to the workup in the study. Main reasons were a
foreseen high rate in false-positive ﬁndings resulting in
increased number of diagnostic procedures, psychologi-
cal distress and costs.
In the LORD study, the use of MRI is allowed in the
workup of the study individuals before randomisation at
the discretion of the physician. The use of MRI after
diagnosis of low-grade DCIS on core biopsy is not
recommended.Fig. 4. Relation between the hazard ratio and the 10-year ipsilateral
invasive breast cancer-free percentage in the standard treatment arm,
for a ﬁxed diﬀerence of 10% in 10-year ipsilateral invasive breast
cancer-free percentage between the standard and experimental arm.
HR = hazard ratio. 10-yr iiBC-free% = 10-year ipsilateral invasive
breast cancer-free percentage.4.7. Statistical considerations
The LORD study comprises some non-conventional
choices in the statistical design.
First, we have applied a special type of non-inferiority
design, where the alternative hypothesis corresponds to
‘minor inferiority’. A classical non-inferiority design
would have had the following H1:
H1classical (non-inferiority of active surveillance):
10-year iiBC-free% active surveillance armP 10-year
iiBC-free% standard arm.
However, we expect slightly more events with an
active surveillance approach as opposed to excision with
or without RT and/or HT in patients with low-gradeFig. 3. Decision tree to be used during follow-uDCIS, and therefore H1classical was not considered real-
istic in this study setting.
Second, the primary test in the LORD study will not
be based on the relative risk (hazard ratio), but on a
ﬁxed diﬀerence in absolute risk (10-year iiBC-free%).
In this trial we expect a low event rate for the primary
end-point, and therefore the absolute diﬀerence in
10-year event-free% is considered to be of more clinical
signiﬁcance than the relative diﬀerence. When the
10-year iiBC-free% in the standard arm would be higher
than anticipated the hazard ratio would increase expo-
nentially, rendering a statistical design based on the haz-
ard ratio, e.g. the logrank test, majorly underpowered.
The outcome of the trial would then not be in line with
the actual diﬀerence in 10-year iiBC-free% (see Fig. 4).
The power of the current proposed statistical test is lessp. ACR = American College of Radiology.
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iiBC-free% in the standard arm (see Table 1).
Third, we chose not to conduct an event-driven trial,
because of the expected low primary event rate in both
study arms. Instead we will use a follow-up
time-driven design. As a result we will greatly depend
on achieving the pre-speciﬁed follow-up for 75% of
patients.
Furthermore, we will primarily test the diﬀerence
between iiBC-free% between both study arms at
10-year follow-up instead of 5-year follow-up. Because
low-grade DCIS has a long natural history, it is neces-
sary to follow up these patients beyond 5 years for late
recurrences, and draw conclusions based on longer
follow-up.
5. Trial status
The start of active recruitment is estimated to be in
the fourth quarter of 2015. Recruitment is estimated to
take 4 years. The projected date of study completion will
be after an additional follow-up period of 10 years.
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